Open AccessVenetoclax (Venclexta)
Author(s) -
Reimbursement Team
Publication year - 2021
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2021.173
Subject(s) - venetoclax , reimbursement , medicine , cytarabine , azacitidine , drug , intensive care medicine , family medicine , chemotherapy , psychiatry , leukemia , political science , health care , biochemistry , gene expression , chemistry , chronic lymphocytic leukemia , law , dna methylation , gene
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.This review assesses venetoclax (Venclexta), 10 mg, 50 mg, and 100 mg oral tablets.Indication: In combination with azacitidine or low-dose cytarabine for the treatment of patients with newly diagnosed AML who are 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.